DK0844875T3 - Anvendelse af L-carnitin og acylderivater til nedsættelse af ceramidniveauer - Google Patents

Anvendelse af L-carnitin og acylderivater til nedsættelse af ceramidniveauer

Info

Publication number
DK0844875T3
DK0844875T3 DK96924125T DK96924125T DK0844875T3 DK 0844875 T3 DK0844875 T3 DK 0844875T3 DK 96924125 T DK96924125 T DK 96924125T DK 96924125 T DK96924125 T DK 96924125T DK 0844875 T3 DK0844875 T3 DK 0844875T3
Authority
DK
Denmark
Prior art keywords
carnitine
lowering
acyl derivatives
ceramide levels
ceramide
Prior art date
Application number
DK96924125T
Other languages
English (en)
Inventor
Sonia Moretti
Original Assignee
Sigma Tau Ind Farmaceuti
Mendes Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Ind Farmaceuti, Mendes Srl filed Critical Sigma Tau Ind Farmaceuti
Application granted granted Critical
Publication of DK0844875T3 publication Critical patent/DK0844875T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK96924125T 1995-08-03 1996-07-19 Anvendelse af L-carnitin og acylderivater til nedsættelse af ceramidniveauer DK0844875T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT95RM000545A IT1277898B1 (it) 1995-08-03 1995-08-03 Uso di amminoacidi basici, di acil derivati di amminoacidi basici e di loro sali farmaceuticamente accettabili per la profilassi di malattie
PCT/IT1996/000147 WO1997005862A2 (en) 1995-08-03 1996-07-19 Use of basic amino acids and derivatives for lowering ceramide levels

Publications (1)

Publication Number Publication Date
DK0844875T3 true DK0844875T3 (da) 2007-04-10

Family

ID=11403513

Family Applications (1)

Application Number Title Priority Date Filing Date
DK96924125T DK0844875T3 (da) 1995-08-03 1996-07-19 Anvendelse af L-carnitin og acylderivater til nedsættelse af ceramidniveauer

Country Status (18)

Country Link
US (2) US6114385A (da)
EP (1) EP0844875B1 (da)
JP (1) JPH11510182A (da)
KR (1) KR100423760B1 (da)
CN (1) CN1138539C (da)
AR (1) AR003473A1 (da)
AT (1) ATE349206T1 (da)
AU (1) AU713207B2 (da)
BR (1) BR9610106A (da)
CA (1) CA2228281C (da)
DE (1) DE69636792T2 (da)
DK (1) DK0844875T3 (da)
ES (1) ES2279523T3 (da)
IT (1) IT1277898B1 (da)
PT (1) PT844875E (da)
RU (1) RU2179850C2 (da)
TW (1) TW434011B (da)
WO (1) WO1997005862A2 (da)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1277897B1 (it) * 1995-08-03 1997-11-12 Mendes Srl Uso della l-carnitina,di suoi derivati e di loro sali farmaceuticamen- te accettabili in combinazione con farmaci antiretrovirali per ridurre
IT1277898B1 (it) 1995-08-03 1997-11-12 Mendes Srl Uso di amminoacidi basici, di acil derivati di amminoacidi basici e di loro sali farmaceuticamente accettabili per la profilassi di malattie
IT1284661B1 (it) * 1996-06-06 1998-05-21 Sigma Tau Ind Farmaceuti Uso di alcanoil l-carnitine nel trattamento terapeutico di malattie infiammatorie croniche intestinali.
FR2778562B1 (fr) * 1998-05-14 2000-08-04 Sephra Composition pharmaceutique, hygienique et/ou cosmetique contenant de l'eau de mer et de l'arginine
DE69923322T2 (de) * 1998-07-30 2005-12-22 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Verwendung von propionyl-l-carnitin und acetyl-l-carnitin zur herstellung von arzneimittel mit antikrebs wirkung
IT1302289B1 (it) 1998-09-30 2000-09-05 Univ Catania Composizioni farmaceutiche ad attivita' antineoplastica
JP2002539257A (ja) * 1999-03-19 2002-11-19 イーノス・ファーマシューティカルス・インコーポレーテッド 薬剤の脳内生物学的利用率の増加
US20010025027A1 (en) * 2000-03-07 2001-09-27 Sonis Stephen T. Inhibition of ceramide for the prevention and treatment of oral mucositis induced by antineoplastic drugs or radiation
JP4419390B2 (ja) * 2001-01-30 2010-02-24 味の素株式会社 炎症性疾患治療予防剤
EP1562555A2 (en) * 2002-10-24 2005-08-17 Enos Pharmaceuticals, Inc. Sustained release l-arginine formulations and methods of manufacture and use
WO2005035001A1 (en) * 2003-09-29 2005-04-21 Enos Pharmaceuticals, Inc. Sustained release l-arginine formulations and methods of manufacture and use
US20080145424A1 (en) * 2002-10-24 2008-06-19 Enos Phramaceuticals, Inc. Sustained release L-arginine formulations and methods of manufacture and use
IL156670A0 (en) * 2003-06-26 2004-01-04 Zvi Zolotariov Aloe suppositories
JP2007055900A (ja) * 2003-12-15 2007-03-08 Ajinomoto Co Inc 炎症性疾患の治療及び予防用医薬組成物
US20050232911A1 (en) * 2004-04-19 2005-10-20 Schreiber Brian D Prevention and treatment of metabolic abnormalities associated with excess intramyocellular lipid
RU2268718C1 (ru) * 2004-11-09 2006-01-27 Казанский государственный медицинский университет Способ предотвращения развития осложнений экспериментального инфаркта миокарда у крыс
EA019268B1 (ru) * 2010-12-01 2014-02-28 Общество С Ограниченной Ответственностью "Анвилаб" Комбинированное средство, обладающее гепатопротекторным действием
CN103142735B (zh) * 2013-03-09 2014-07-23 河北工程大学 一种治疗鸭病毒性肝炎的中药口服液
EP3764103A1 (en) * 2019-07-12 2021-01-13 Urgo Recherche Innovation Et Developpement Method of diagnosis or prognosis of a non-healing or chronic wound
EP4125858B1 (en) * 2020-04-28 2026-05-06 Lonza Greenwood LLC Nutritional composition comprising l-carnitine tartrate for use in treating or preventing a coronavirus infection in a mammal
WO2023244536A2 (en) * 2022-06-13 2023-12-21 Neubase Therapeutics, Inc. Oligonucleotide analogue formulations

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU518617B2 (en) * 1977-04-29 1981-10-08 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Therapeutic application of acetyl-d, 1-carnitine
DE2946563C2 (de) * 1979-11-17 1987-04-30 B. Braun Melsungen Ag, 3508 Melsungen Aminosäurelösung zur parenteralen Infusion
JPH0247447B2 (ja) * 1982-05-27 1990-10-19 Teijin Ltd Kohotaikanohikuiigmsoseibutsu
JPS6130567A (ja) * 1984-07-23 1986-02-12 Shiseido Co Ltd 尿素の安定化法
JPH02124822A (ja) * 1988-11-02 1990-05-14 Eisai Co Ltd セファロスポリン含有注射用組成物
IT1224842B (it) * 1988-12-27 1990-10-24 Sigma Tau Ind Farmaceuti Uso di derivati della l-carnitina nel trattamento terapeutico delle alterazioni degenerative del sistema nervoso
US6294520B1 (en) * 1989-03-27 2001-09-25 Albert T. Naito Material for passage through the blood-brain barrier
EP0400547A1 (en) * 1989-06-02 1990-12-05 Abbott Laboratories Parenteral nutrition product
IT1244636B (it) * 1991-01-04 1994-08-08 Sigma Tau Ind Farmaceuti Uso dell'acetil l-carnitina nel trattamento terapeutico del coma e composizioni farmaceutiche utili in tale trattamento.
IT1248321B (it) * 1991-05-15 1995-01-05 Sigma Tau Ind Farmaceuti Uso di esteri di acil l-carnitine con l'acido gamma-idrossibutirrico per produrre composizioni farmaceutiche per il trattamento di epatopatie
IT1245869B (it) * 1991-06-05 1994-10-25 Sigma Tau Ind Farmaceuti Impiego di propionil l-carnitina per il recupero del tono muscolare in soggetti immobilizzati
IT1254136B (it) * 1992-01-16 1995-09-08 Sigma Tau Ind Farmaceuti Esteri di acil carnitine con alcooli alifatici a lunga catena e composizioni farmaceutiche che li contengono, ad attivita' antimicotica.
AU6922994A (en) * 1993-06-21 1995-01-17 Bernardini, Attilio Use of acylcarnitin to treat illnesses caused by aids
IT1277897B1 (it) 1995-08-03 1997-11-12 Mendes Srl Uso della l-carnitina,di suoi derivati e di loro sali farmaceuticamen- te accettabili in combinazione con farmaci antiretrovirali per ridurre
IT1277898B1 (it) 1995-08-03 1997-11-12 Mendes Srl Uso di amminoacidi basici, di acil derivati di amminoacidi basici e di loro sali farmaceuticamente accettabili per la profilassi di malattie
IT1283951B1 (it) * 1996-03-15 1998-05-07 Mendes Srl Uso della acetil l-carnitina o dei suoi sali farmacologicamente accettabili per il trattamento terapeutico o la profilassi di

Also Published As

Publication number Publication date
WO1997005862A2 (en) 1997-02-20
US6350782B1 (en) 2002-02-26
EP0844875B1 (en) 2006-12-27
MX9800916A (es) 1998-10-31
ES2279523T3 (es) 2007-08-16
AU713207B2 (en) 1999-11-25
CN1138539C (zh) 2004-02-18
KR100423760B1 (ko) 2004-08-25
CA2228281C (en) 2008-03-25
PT844875E (pt) 2007-02-28
KR19990036148A (ko) 1999-05-25
IT1277898B1 (it) 1997-11-12
CN1193911A (zh) 1998-09-23
CA2228281A1 (en) 1997-02-20
RU2179850C2 (ru) 2002-02-27
BR9610106A (pt) 1999-02-23
WO1997005862A3 (en) 1997-04-17
ATE349206T1 (de) 2007-01-15
AR003473A1 (es) 1998-08-05
EP0844875A2 (en) 1998-06-03
JPH11510182A (ja) 1999-09-07
DE69636792T2 (de) 2007-10-04
TW434011B (en) 2001-05-16
ITRM950545A0 (it) 1995-08-03
AU6469196A (en) 1997-03-05
HK1015274A1 (en) 1999-10-15
ITRM950545A1 (it) 1997-02-03
US6114385A (en) 2000-09-05
DE69636792D1 (de) 2007-02-08

Similar Documents

Publication Publication Date Title
DK108997A (da) Fremstilling og krystalformer af 2-methylthien-benzodiazepin
DK1167364T3 (da) Benzopyranholdige forbindelser og promedikamentformer af disse
NO975331D0 (no) Anvendelse av R-enantiomer av N-propargyl-1-aminoindan salter og sammensetninger derav
NO973794D0 (no) Innretning og fremgangsmåte for testing
NO963857D0 (no) Rörleggingsfartöy og fremgangsmåte
UA28054C2 (uk) Кондитерський виріб та спосіб його одержання
KR960007486A (ko) 코팅된 지지체 및 상기의 형성 방법
FI970112A7 (fi) Helico-bakeerin vastaisia atsolonien asyylijohdannaisia
BR9303442A (pt) Aplicacao de aminas graxas oxalquiladas e de derivados de aminas graxas
DK0702344T3 (da) Etiketkontinuum og fremgangsmåde til fremstilling deraf
ATE349206T1 (de) Verwendung von l-carnitine und acyl derivaten zur senkung des ceramidspiegels
NO972477D0 (no) Meso-mono-jod substituerte tetramakrocykliske forbindelser og fremgangsmåter for fremstilling og anvendelse
DK0821664T3 (da) Fremgangsmåde til fremstilling af aminoethylethanolamin og/eller hydroxyethylenpiperazin
DK0805797T3 (da) Fremgangsmåde til fremstilling af N-aryl- og N-hetarylhydroxylaminer
BR9609053A (pt) Métodos de induzir fator de transcrição de bef-1
FR2757059B1 (fr) Nouvelle application therapeutique des derives du pyrrole
NO994599L (no) Anordning og fremgangsmåte for prosodigenering av visuell syntese
FI963995L (fi) Atsolonien helikobakteeria vastustavat esteri- ja karbamaattijohdannaiset
DK0839033T3 (da) Anvendelse af L-carnitin og derivater til reducering af ceramidniveauer og potensering af antiretroviral virkning
BR9611616A (pt) Elemento de suporte e estrutura de suporte de tubulação
DK0840609T3 (da) Anvendelse af usubstituerede og substituerede N-(pyrrol-1-yl)pyridinaminer som antikonvulsive midler
KR970048281U (ko) 비디오 및 그래픽디코더의 기준클럭 제공장치
FI945956A7 (fi) Furoimidatsolijohdosten asymmetrinen hydraus
FI942238A0 (fi) Furoimidatsolijohdannaisten asymmetrinen hydraus
DK0983999T3 (da) Fremgangsmåde til fremstilling af amidderivater og mellemprodukter